Latest Breaking News On - Poster discussion - Page 1 : comparemela.com

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan franciscoDouglase onsiMatthew deyoungMeredith pelsterMsc sarah cannon research instituteAmerican society of clinical oncologyPrnewswire leap therapeutics incDrug administrationLeap therapeutics incClinical oncologyGastrointestinal cancersPresentation detailsSarah cannon research institutePoster discussion

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449 s Potential as a New Treatment for Drug-Resistant NSCLC

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

United statesLi zhangWestern australiaHong kongYifan zhaiAscentage pharmaNational reimbursement drug listAmerican society of clinical oncologySun yat sen university cancer centerChina national medical products administrationMajor nationalMd anderson cancer centerDana farber cancer institutePoster discussionAmerican societyClinical oncology

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.

United statesChunlei liValerie malyvanh jansenYakun wangElevation oncology incCorporate communications investor relationsAmerican society of clinical oncologyPrnewswire elevation oncology incExchange commissionGroup limitedDrug administrationAmerican societyClinical oncologyChief medical officerElevation oncologyChief scientific officer

New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types

Highlights include oral presentations in Sarcoma and CRC; immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study; updates from the CIRCULATE-Japan study in CRC . | May 30, 2023

United statesSan carlosAmerican society of clinical oncologyNatera incClinical laboratory improvement amendmentsAssociation of tumorClinical oncologyAnnual meetingMinetta liuPoster discussionHigh ratesUndiagnosed concomitant radiographic recurrencesOral presentationSoft tissue sarcomaPoster presentationClinical outcomes

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.

South koreaUnited statesMccormick placeHong kongPeter qianAsia pacificHong kong stock exchangePrnewswire antengene corporation limitedCompany annualEastern cooperative oncology groupAntengene corporation limitedAmerican society for clinical oncology annual meetingAntengene corporationMccormick place convention centerCorporation limitedClinical oncology annual meeting